ANALISIS EFEKTIVITAS BIAYA (COST EFFECTIVENESS ANALYSIS) PENGOBATAN PNEUMONIA MENGGUNAKAN ANTIBIOTIK SEFTRIAKSON DAN SEFOTAKSIM DI RSUP PROF. DR. R. D. KANDOU MANADO

Authors

  • Amelia Nalang

DOI:

https://doi.org/10.35799/pha.7.2018.20599

Abstract

ANALISIS EFEKTIVITAS BIAYA (COST EFFECTIVENESS ANALYSIS) PENGOBATAN PNEUMONIA MENGGUNAKAN ANTIBIOTIK SEFTRIAKSON DAN SEFOTAKSIM DI RSUP PROF. DR. R. D. KANDOU MANADO

Amelia Nalang 1), Gayatri Citraningtyas 1), Widya Astuty Lolo 1)
1)Program Studi Farmasi FMIPA UNSRAT Manado, 95115

ABSTRACT

Pneumonia is an infection of the lower respiratory tract, which affects the lung tissue. The antibiotics Ceftriaxone and Cefotaxime are the most common and good antibiotics used in the treatment of pneumonia, both of these antibiotics are not known which one is the more cost-effective as the treatment options yet, so Cost-effectiveness analysis is needed in order to facilitate the selection of the more cost-effective treatment alternative, especially in children. This study aims to determine the more cost-effective treatment of the use of the antibiotics Ceftriaxone and Cefotaxime against pneumonia patients at Prof. Dr. R. D. Kandou Hospital, Manado. This study uses a descriptive research method with a retrospective retrieval. The sample of this study consists of 40 patients, with 20 patients using antibiotics Ceftriaxone and 20 patients were using Cefotaxime. The results show that the treatment of pneumonia in children is more cost-effectiveness using antibiotics Cefotaxime with the value of ACER for Rp. 35,428 and ICER value of - Rp.16.235.

Keywords: Cost Effectiveness Analysis, Ceftriaxone, Cefotaxime, Pneumonia

ABSTRAK

Pneumonia merupakan penyakit infeksi pada saluran pernapasan bagian bawah yang mengenai jaringan paru. Antibiotik Seftriakson dan Sefotaksim merupakan antibiotik yang paling banyak dan baik untuk digunakan dalam pengobatan pneumonia, namun dari kedua antibiotik tersebut belum diketahui pilihan terapi yang lebih cost-effective, sehingga perlu dilakukan analisis efektivitas biaya agar dapat mempermudah dalam pemilihan alternatif pengobatan yang lebih cost-effective khususnya pada balita. Penelitian ini bertujuan untuk menentukan terapi yang lebih cost-effective dari penggunaan antibiotik Seftriakson dan Sefotaksim pada pasien pneumonia rawat inap di RSUP Prof. Dr. R. D. Kandou Manado. Penelitian ini menggunakan metode penelitian deskriptif dengan pengambilan data secara retrospektif. Sampel pada penelitian ini sebanyak 40 pasien yaitu 20 pasien menggunakan antibiotik Seftriakson dan 20 pasien menggunakan antibiotik Sefotaksim. Hasil penelitian menunjukkan bahwa pengobatan pneumonia pada balita menggunakan antibiotik Sefotaksim lebih cost-effective dengan nilai ACER sebesar Rp. 35.428 dan nilai ICER sebesar Rp. -16.235.

Kata Kunci: Analisis Efektivitas Biaya, Seftriakson, Sefotaksim, Pneumonia

 

 

Downloads

Published

2018-07-01

How to Cite

Nalang, A. (2018). ANALISIS EFEKTIVITAS BIAYA (COST EFFECTIVENESS ANALYSIS) PENGOBATAN PNEUMONIA MENGGUNAKAN ANTIBIOTIK SEFTRIAKSON DAN SEFOTAKSIM DI RSUP PROF. DR. R. D. KANDOU MANADO. PHARMACON, 7(3). https://doi.org/10.35799/pha.7.2018.20599

Issue

Vol. 7 No. 3 (2018): Pharmacon

Section

Articles

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)